[ad_1] The US Food and Drug Administration (FDA) has approved galcanezumab-gnlm, an antagonist of calcitonin gene-related peptides (CGRP) (Emgalité, Eli Lilly and Co) for the prevention of migraine in adult patients, reports …
Read More »FDA's Greencan Galaxezumab (Emgality) for the Prevention of Migraine
